Shirley Clayton

Prior to joining the board in February 2007, Ms. Clayton retired as President and Chief Executive Officer of Abmaxis, Inc., which was acquired by Merck & Co. As VP and Treasurer at Genentech, Inc., the first biopharmaceutical company, Ms. Clayton was actively involved in the early financing of the biotechnology industry. Prior to her role at Abmaxis, she co-founded Raven Biotechnologies, a cell biology company developing monoclonal antibody products, and served as its President and Chief Financial Officer.

During her 25 years as an executive in the life science industry, Ms. Clayton was Chief Financial Officer, President or Chief Executive Officer in several companies including Protein Design Labs, now PDL BioPharma, Inc.; Cygnus, Inc., a drug delivery company; and CBYON, a medical technology company sold to GE Medical Systems.

She is a member of the Board and Audit committee of Metro Bancorp and a member of the Board of Metro United Bank and Chairman of its Credit committee. Ms. Clayton received a BS in Chemistry from Smith College and an MBA from the Stanford University Graduate School of Business.

Shirley Clayton is the Board of Directors at REGiMMUNE. With a background in Biotechnology, Shirley Clayton has a rich history of leadership and innovation. Shirley Clayton studied BS Chemistry @ Smith College. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.